News & Updates
Showing Oncology articles
Showing

Add-on tafasitamab–lenalidomide improves PFS in BCLs
In the global phase III frontMIND study, adding tafasitamab and lenalidomide (Tafa-Len) to an R-CHOP* chemotherapy regimen significantly improves progression-free survival in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade BCL (HGBCL).

Tebentafusp delivers 5-year survival benefit in metastatic uveal melanoma
Long-term survival benefits with tebentafusp persist in previously untreated HLA-A∗02:01-positive patients with unresectable or metastatic uveal melanoma (mUM), as shown in the longest survival follow-up of a phase III trial.

Lorlatinib delivers long-term survival benefits in advanced ALK-positive NSCLC
First-line treatment with lorlatinib demonstrates long-term survival benefits in patients with advanced anaplastic lymphoma kinase (ALK)-positive nonsmall cell lung cancer (NSCLC), as shown in the 7-year update from the phase III CROWN study.





